Prognostic value of morphology and hormone receptor status in breast cancer -: a population-based study

被引:34
作者
Allemani, C
Sant, M
Berrino, F
Aareleid, T
Chaplain, G
Coebergh, JW
Colonna, M
Contiero, P
Danzon, A
Federico, M
Gafà, L
Grosclaude, P
Hédelin, G
Macè-Lesech, J
Garcia, CM
Paci, E
Raverdy, N
Tretarre, B
Williams, EMI
机构
[1] Ist Nazl Studio & Cura Tumori, Epidemiol Unit, I-20133 Milan, Italy
[2] Inst Clin & Expt Med, Dept Epidemiol & Biostat, EE-11619 Tallinn, Estonia
[3] N Estonian Reg Hosp Fdn Canc Ctr, Estonian Canc Registry, EE-11619 Tallinn, Estonia
[4] Fac Med, Ctr Univ Epidemiol Populat, Cote dOr Breast & Gynaecol Canc Registry, F-21000 Dijon, France
[5] Eindhoven Canc Registry, Comprehens Canc Ctr S, NL-5600 EA Eindhoven, Netherlands
[6] Isere Canc Registry, F-38240 Meylan, France
[7] Ist Nazl Studio & Cura Tumori, Lombardy Canc Registry, I-20133 Milan, Italy
[8] CHU Besancon, Doubs Canc Registry, F-25030 Besancon, France
[9] Policlin, Modena Canc Registry, I-41100 Modena, Italy
[10] Ragusa Canc Registry, I-97100 Ragusa, Italy
[11] Tam Canc Registry Rech Epidemiol & Prevent, F-81001 Albi, France
[12] Fac Med Strasbourg, Bas Rhin Canc Registry, Lab Epidemiol & Sante Publ, F-67085 Strasbourg, France
[13] Ctr Francois Baclesse, Calvados Canc Registry, F-14021 Caen, France
[14] Escuela Andaluza SAlud Publ, Granada Canc Registry, E-18080 Granada, Spain
[15] Ao Careggi CSPO, UO Epidemiol Clin & Descritt, Tuscany Canc Registry, I-50135 Florence, Italy
[16] CHR Nord, Assoc Rech Epidemiol Picardie, Somme Canc Registry, F-80054 Amiens 1, France
[17] Herault Canc Registry, F-34298 Montpellier 5, France
[18] Univ Liverpool, Mersey Canc Registry, Liverpool L69 3GB, Merseyside, England
关键词
breast cancer; population-based studies; relative survival; predictive factors; relative excess risk of death;
D O I
10.1038/sj.bjc.6602153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990-1992 from cancer registries in Estonia, France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular plus mixed carcinoma, comedocarcinoma, 'special types', medullary carcinoma, not otherwise specified (NOS) carcinoma, other carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61-71) for NOS carcinoma to 95% (95% CI 90-100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27% (95% CI 18-36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age and stage at diagnosis.
引用
收藏
页码:1263 / 1268
页数:6
相关论文
共 35 条
  • [21] The importance of histologic type on breast cancer survival
    Northridge, ME
    Rhoads, GG
    Wartenberg, D
    Koffman, D
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (03) : 283 - 290
  • [22] Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer
    Pedersen, L
    Zedeler, K
    Holck, S
    Schiodt, T
    Mouridsen, HT
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2289 - 2295
  • [23] Percy C., 1990, International classification of diseases for oncology
  • [24] TYPICAL MEDULLARY CARCINOMA OF THE BREAST - A CLINICAL AND PATHOLOGICAL ANALYSIS OF 52 CASES
    REINFUSS, M
    STELMACH, A
    MITUS, J
    RYS, J
    DUDA, K
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1995, 60 (02) : 89 - 94
  • [25] RUDER AM, 1989, CANCER, V64, P196, DOI 10.1002/1097-0142(19890701)64:1<196::AID-CNCR2820640134>3.0.CO
  • [26] 2-3
  • [27] Breast carcinoma survival in Europe and the United States -: A population-based study
    Sant, M
    Allemani, C
    Berrino, F
    Coleman, MP
    Aareleid, T
    Chaplain, G
    Coebergh, JW
    Colonna, M
    Crosignani, P
    Danzon, A
    Federico, M
    Gafà, L
    Grosclaude, P
    Hédelin, G
    Macè-Lesech, J
    Garcia, CM
    Moller, H
    Paci, E
    Raverdy, N
    Tretarre, B
    Williams, EMI
    [J]. CANCER, 2004, 100 (04) : 715 - 722
  • [28] Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe
    Sant, M
    Allemani, C
    Capocaccia, R
    Hakulinen, T
    Aareleid, T
    Coebergh, JW
    Coleman, MP
    Grosclaude, P
    Martinez, C
    Bell, J
    Youngson, J
    Berrino, F
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (03) : 416 - 422
  • [29] Differences in stage and therapy for breast cancer across Europe
    Sant, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (06) : 894 - 901
  • [30] SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P1673, DOI 10.1002/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO